Evidence Level
Pygeum has one of the strongest evidence bases among prostate supplements, anchored by the 2002 Cochrane review by Wilt et al. This systematic review analyzed 18 randomized controlled trials involving 1,562 men with BPH and concluded that pygeum bark extract (typically 100mg daily standardized to Tadenan specifications) provided statistically significant improvements in overall urological symptoms (65% of pygeum users reported improvement vs. 30% for placebo), nocturia (19% reduction), residual urine volume (24% reduction), and peak urine flow (23% increase). The extract is an approved pharmaceutical product in France (Tadenan), Germany, and Italy, where it is covered by national health insurance. Edgar et al. (2007) published a detailed analysis of pygeum's mechanism, confirming anti-inflammatory effects via 5-LOX inhibition and anti-proliferative effects via growth factor inhibition. Sustainability is a concern — Prunus africana is listed under CITES Appendix II due to overharvesting, and ethical sourcing should be verified.